🏢 官网IRINSPCodex · 实盘不做把握 3/10
北京时间·🕒 发布 20:00:00时区推断·⟳ 抓取 20:01:44·⚡ 决策 07-27 20:02:21 +37s·92.0 天前
Inspire Medical Systems任命医疗器械高管Michael H. Carrel加入董事会
本次事件是董事会任命公告，属于治理与品牌背书信息，没有披露订单、业绩指引、监管获批或可量化商业增量。
📄 原文INSP↗ 原文
Board appointment adds proven medical device leadership MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical…
不做 Inspire Medical Systems（INSP.US）
常规董事会任命没有明确、可量化的短周期经营传导，也没有同向可执行交易边界，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次事件是董事会任命公告，属于治理与品牌背书信息，没有披露订单、业绩指引、监管获批或可量化商业增量。
主要风险
- 董事任命本身通常不构成短线重定价催化，无法形成可回测的正期望交易。
原文全文
展开原文 · 2,708 字
Board appointment adds proven medical device leadership MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of seasoned medical device executive Michael H. Carrel to its Board of Directors effective July 20.
“We are pleased to welcome Mr. Carrel to our Board of Directors,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies, and we look forward to his guidance as we continue advancing Inspire therapy for the many patients affected by OSA.”
Mr. Carrel has served as President, Chief Executive Officer, and a director of AtriCure, Inc. (NASDAQ: ATRC), an innovative cardiac device company, since November 2012. Under Mr. Carrel’s leadership, AtriCure has advanced a robust pipeline of novel products for the treatment of atrial fibrillation, left atrial appendage management and pain management. During his tenure, AtriCure has grown from $82 million in revenue in 2013 to $535 million in 2025 while helping more than one million patients.
Previously, Mr. Carrel served as Chairman of the Board of Directors of Axonics, Inc. from 2019 through 2024, until its sale to Boston Scientific Corporation. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School of the University of Pennsylvania.
“I am excited to join Inspire at this important stage in the Company’s growth,” said Mr. Carrel. “With the recent launch of the fifth-generation Inspire device, a compelling product pipeline and a growing body of evidence demonstrating the long-term benefits of Inspire therapy, particularly in cardiovascular health, I believe the Company is well positioned to continue expanding access to care for patients with OSA.”
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com .
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
Source: Inspire Medical Systems
“We are pleased to welcome Mr. Carrel to our Board of Directors,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies, and we look forward to his guidance as we continue advancing Inspire therapy for the many patients affected by OSA.”
Mr. Carrel has served as President, Chief Executive Officer, and a director of AtriCure, Inc. (NASDAQ: ATRC), an innovative cardiac device company, since November 2012. Under Mr. Carrel’s leadership, AtriCure has advanced a robust pipeline of novel products for the treatment of atrial fibrillation, left atrial appendage management and pain management. During his tenure, AtriCure has grown from $82 million in revenue in 2013 to $535 million in 2025 while helping more than one million patients.
Previously, Mr. Carrel served as Chairman of the Board of Directors of Axonics, Inc. from 2019 through 2024, until its sale to Boston Scientific Corporation. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School of the University of Pennsylvania.
“I am excited to join Inspire at this important stage in the Company’s growth,” said Mr. Carrel. “With the recent launch of the fifth-generation Inspire device, a compelling product pipeline and a growing body of evidence demonstrating the long-term benefits of Inspire therapy, particularly in cardiovascular health, I believe the Company is well positioned to continue expanding access to care for patients with OSA.”
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com .
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
Source: Inspire Medical Systems
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。